Fresh analysis reveals that people who discontinue new GLP-1 drugs like Mounjaro or Wegovy may regain lost weight at a significantly accelerated pace than those who end traditional lifestyle plans.
Findings released in a prominent health publication shows that while obese people frequently drop a large proportion of their body weight while on the medication, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Users purchasing such treatments should be aware of the danger of rapid weight regain when the treatment concludes," stated researcher Dr. Susan Jebb.
This pace of recovery implies a return to starting weight within about 18 months.
Weighing Treatments
The study, which examined 37 of trials involving thousands of participants, compared the results of GLP-1 agonists with older methods.
The team point out that people who lose weight through dieting generally experience a slower weight regain—around 0.1 kg a month—after stopping.
Explaining the Rapid Rebound
Experts believe the mechanism of the jabs is key to understanding the accelerated regain.
The injections mimic a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing the hormone concentrations several times higher than the body's typical production could lead to the body to produce less of its own natural hormone, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication results in hunger is uncontrolled, making binge eating much more probable."
A Chronic Disease?
The NHS suggest the injections for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians say that, given the likelihood of weight regain, the treatment is often long-term.
This opinion is reinforced by drug manufacturers, who say that the findings "highlight the persistent nature of obesity," comparing it to managing conditions like diabetes.
User Testimonies
Users who have stopped the medication report a powerful resurgence of cravings.
"It was like something activating and you become starving," recalled one woman.
The struggle is compounded if users have not adopted permanent dietary or behavioural changes during therapy.
Widespread Adoption
Survey data suggest that millions of people in the UK have used these injections in the last 12 months, with desire being substantial.
- Adoption is more common among women than males.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
In conclusion, researchers caution that while the jabs are potent tools for shedding pounds, they are not a permanent solution and maintained weight loss hinges on integrated lifestyle management.
